MiP Pharma's Sterile Production Site

Based in Germany, MiP Pharma's Sterile Production Site focuses on the development and distribution of high-quality sterile pharmaceuticals, particularly in the antibiotic sector, catering to healthcare professionals across Europe. MiP Pharma's Sterile Production Site specializes in sterile pharmaceutical production and has been operational since its founding in 2012. The company has a single significant deal recorded, with the most recent being on May 13, 2025, marking its strategic growth in sterile manufacturing capabilities. Currently headquartered in Germany, it does not operate as a subsidiary or through any mergers, nor does it have publicly available details on a founder or CEO.

MiP Pharma Unternehmensgruppe specializes in the development and distribution of high-quality pharmaceuticals, focusing primarily on antibiotics. Their product portfolio is tailored to address specific medical needs within the healthcare sector, particularly targeting select specialist physician groups such as dentists and urologists, as well as the clinical market. The company has been operational since 1955 and has expanded its market reach from Germany to various international locations, including Poland and other Eastern European markets. This strategic expansion is part of their commitment to ensure a reliable supply of essential medications within Europe.

MiP Pharma employs a dedicated team of 150 professionals to support these operations, ensuring adherence to strict quality standards and customer service. MiP Pharma Unternehmensgruppe reports an annual revenue of approximately EUR 50 mn. The company's revenue model is primarily based on direct business-to-business interactions with healthcare providers and institutions, facilitating the distribution of their pharmaceutical products. Transactions typically occur through established partnerships with hospitals and clinics, where MiP Pharma supplies its medicines in bulk, ensuring timely delivery and compliance with healthcare regulations.

The company maintains a strong reputation for reliability and customer orientation, which has earned it accolades as a leading supplier in the clinic sector in Germany. While specific pricing structures for their products have not been disclosed, the firm’s focus on specialized markets allows it to position its products competitively to meet the needs of its clients. In May 2025, Famar S. A.

, a portfolio company of KKR, Mid Europa, Metric Capital Partners, EBRD, and Elements Capital Partners, acquired MiP Pharma's Sterile Production Site. This acquisition enhances Famar's sterile manufacturing capabilities and strengthens its presence in the European pharmaceutical market. Future growth plans include the introduction of new antibiotic products tailored for specific medical needs and expanding distribution to additional Eastern European markets. Funds from the recent acquisition will support these initiatives, particularly in enhancing manufacturing operations and broadening market reach.